Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI

Objective Tocilizumab (TCZ) is effective in patients with rheumatoid arthritis (RA) who are refractory to anti-tumor-necrosis-factor (anti-TNF) biologics. The Rheumatoid Arthritis Society Disease Activity Score in 28 Joints (DAS28) is used to evaluate the response to TCZ. However, DAS28 is inappropr...

Full description

Saved in:
Bibliographic Details
Published in:Modern rheumatology 2013-07, Vol.23 (4), p.782-787
Main Authors: Suzuki, Takeshi, Horikoshi, Masanobu, Sugihara, Makoto, Hirota, Tomoya, Ogishima, Hiroshi, Umeda, Naoto, Kondo, Yuya, Tsuboi, Hiroto, Hayashi, Taichi, Chino, Yusuke, Matsumoto, Isao, Sumida, Takayuki
Format: Article
Language:English
Subjects:
Medicine
Medicine & Public Health
Original Article
Orthopedics
Rheumatology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-p231t-5175cc8bf5c593d462684d5549953b42c8cf8c3e2a8619ca2b0f3b9b79a42a083
container_end_page 787
container_issue 4
container_start_page 782
container_title Modern rheumatology
container_volume 23
creator Suzuki, Takeshi
Horikoshi, Masanobu
Sugihara, Makoto
Hirota, Tomoya
Ogishima, Hiroshi
Umeda, Naoto
Kondo, Yuya
Tsuboi, Hiroto
Hayashi, Taichi
Chino, Yusuke
Matsumoto, Isao
Sumida, Takayuki
description Objective Tocilizumab (TCZ) is effective in patients with rheumatoid arthritis (RA) who are refractory to anti-tumor-necrosis-factor (anti-TNF) biologics. The Rheumatoid Arthritis Society Disease Activity Score in 28 Joints (DAS28) is used to evaluate the response to TCZ. However, DAS28 is inappropriate marker because TCZ normalizes C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in the early stage of treatment. The aim of our study was to test the usefulness of magnetic resonance imaging (MRI)-based markers of response to TCZ treatment. Methods Nine patients with RA who were refractory to anti-TNF inhibitors (six to infliximab, one to etanercept, one to adalimumab, and one to both) were assessed. MRI images of both hands were obtained by low-field extremity MRI at baseline, 20, and 44 weeks of treatment, in addition to assessment with DAS28–ESR. The effect of TCZ on RA was examined by compact MRI score (cMRIS). Results All patients showed good or moderate response to TCZ treatment, as evaluated by significant reduction in DAS28–ESR at both 20 and 44 weeks ( p  
doi_str_mv 10.1007/s10165-012-0746-2
format article
fullrecord <record><control><sourceid>proquest_sprin</sourceid><recordid>TN_cdi_proquest_miscellaneous_1401089976</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1401089976</sourcerecordid><originalsourceid>FETCH-LOGICAL-p231t-5175cc8bf5c593d462684d5549953b42c8cf8c3e2a8619ca2b0f3b9b79a42a083</originalsourceid><addsrcrecordid>eNo1kctKxDAUhosoeH0Ad1m6iebStI07EW-gCKLrkGZO7JFOU5MUHZ_Jh7Tj6Or88F848BXFMWennLH6LHHGK0UZF5TVZUXFVrHHS6lpXTG9_a-VVrvFfkpvjEmlG71XfD93EO0IU0ZHwHt01q1I8CQHhz1-TUvbEhzIaDPCkBP5wNyR2MFs5IALYmPuImZMJIKP1uUQV3OZ2CEjzdMyRDqAiyFhov7Xnuc6bHFW6ZxwsgIbiQ99Hz7oNG7219oj9AsCnznCEvOKPDzdHRY73vYJjv7uQfFyffV8eUvvH2_uLi_u6Sgkz1TxWjnXtF45peWirETVlAulSq2VbEvhGucbJ0HYpuLaWdEyL1vd1tqWwrJGHhQnm90xhvcJUjZLTA763g4QpmR4yThrtK6rOSo20TRGHF4hmrcwxWH-znBm1mjMBo2Z0Zg1GiPkD2IMhmE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1401089976</pqid></control><display><type>article</type><title>Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI</title><source>Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)</source><creator>Suzuki, Takeshi ; Horikoshi, Masanobu ; Sugihara, Makoto ; Hirota, Tomoya ; Ogishima, Hiroshi ; Umeda, Naoto ; Kondo, Yuya ; Tsuboi, Hiroto ; Hayashi, Taichi ; Chino, Yusuke ; Matsumoto, Isao ; Sumida, Takayuki</creator><creatorcontrib>Suzuki, Takeshi ; Horikoshi, Masanobu ; Sugihara, Makoto ; Hirota, Tomoya ; Ogishima, Hiroshi ; Umeda, Naoto ; Kondo, Yuya ; Tsuboi, Hiroto ; Hayashi, Taichi ; Chino, Yusuke ; Matsumoto, Isao ; Sumida, Takayuki</creatorcontrib><description>Objective Tocilizumab (TCZ) is effective in patients with rheumatoid arthritis (RA) who are refractory to anti-tumor-necrosis-factor (anti-TNF) biologics. The Rheumatoid Arthritis Society Disease Activity Score in 28 Joints (DAS28) is used to evaluate the response to TCZ. However, DAS28 is inappropriate marker because TCZ normalizes C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in the early stage of treatment. The aim of our study was to test the usefulness of magnetic resonance imaging (MRI)-based markers of response to TCZ treatment. Methods Nine patients with RA who were refractory to anti-TNF inhibitors (six to infliximab, one to etanercept, one to adalimumab, and one to both) were assessed. MRI images of both hands were obtained by low-field extremity MRI at baseline, 20, and 44 weeks of treatment, in addition to assessment with DAS28–ESR. The effect of TCZ on RA was examined by compact MRI score (cMRIS). Results All patients showed good or moderate response to TCZ treatment, as evaluated by significant reduction in DAS28–ESR at both 20 and 44 weeks ( p  &lt; 0.001, each, relative to baseline). In contrast, MRI-based indexes (e.g., cMRIS, synovitis, edema, erosion scores) improved significantly at 44 weeks but not at 20 weeks. Conclusion Differences in response to TCZ therapy were determined based on the method of evaluation, suggesting that MRI-based markers are potentially useful for evaluating RA response to TCZ therapy.</description><identifier>ISSN: 1439-7595</identifier><identifier>EISSN: 1439-7609</identifier><identifier>DOI: 10.1007/s10165-012-0746-2</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Medicine ; Medicine &amp; Public Health ; Original Article ; Orthopedics ; Rheumatology</subject><ispartof>Modern rheumatology, 2013-07, Vol.23 (4), p.782-787</ispartof><rights>Japan College of Rheumatology 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-p231t-5175cc8bf5c593d462684d5549953b42c8cf8c3e2a8619ca2b0f3b9b79a42a083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Suzuki, Takeshi</creatorcontrib><creatorcontrib>Horikoshi, Masanobu</creatorcontrib><creatorcontrib>Sugihara, Makoto</creatorcontrib><creatorcontrib>Hirota, Tomoya</creatorcontrib><creatorcontrib>Ogishima, Hiroshi</creatorcontrib><creatorcontrib>Umeda, Naoto</creatorcontrib><creatorcontrib>Kondo, Yuya</creatorcontrib><creatorcontrib>Tsuboi, Hiroto</creatorcontrib><creatorcontrib>Hayashi, Taichi</creatorcontrib><creatorcontrib>Chino, Yusuke</creatorcontrib><creatorcontrib>Matsumoto, Isao</creatorcontrib><creatorcontrib>Sumida, Takayuki</creatorcontrib><title>Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI</title><title>Modern rheumatology</title><addtitle>Mod Rheumatol</addtitle><description>Objective Tocilizumab (TCZ) is effective in patients with rheumatoid arthritis (RA) who are refractory to anti-tumor-necrosis-factor (anti-TNF) biologics. The Rheumatoid Arthritis Society Disease Activity Score in 28 Joints (DAS28) is used to evaluate the response to TCZ. However, DAS28 is inappropriate marker because TCZ normalizes C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in the early stage of treatment. The aim of our study was to test the usefulness of magnetic resonance imaging (MRI)-based markers of response to TCZ treatment. Methods Nine patients with RA who were refractory to anti-TNF inhibitors (six to infliximab, one to etanercept, one to adalimumab, and one to both) were assessed. MRI images of both hands were obtained by low-field extremity MRI at baseline, 20, and 44 weeks of treatment, in addition to assessment with DAS28–ESR. The effect of TCZ on RA was examined by compact MRI score (cMRIS). Results All patients showed good or moderate response to TCZ treatment, as evaluated by significant reduction in DAS28–ESR at both 20 and 44 weeks ( p  &lt; 0.001, each, relative to baseline). In contrast, MRI-based indexes (e.g., cMRIS, synovitis, edema, erosion scores) improved significantly at 44 weeks but not at 20 weeks. Conclusion Differences in response to TCZ therapy were determined based on the method of evaluation, suggesting that MRI-based markers are potentially useful for evaluating RA response to TCZ therapy.</description><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Rheumatology</subject><issn>1439-7595</issn><issn>1439-7609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNo1kctKxDAUhosoeH0Ad1m6iebStI07EW-gCKLrkGZO7JFOU5MUHZ_Jh7Tj6Or88F848BXFMWennLH6LHHGK0UZF5TVZUXFVrHHS6lpXTG9_a-VVrvFfkpvjEmlG71XfD93EO0IU0ZHwHt01q1I8CQHhz1-TUvbEhzIaDPCkBP5wNyR2MFs5IALYmPuImZMJIKP1uUQV3OZ2CEjzdMyRDqAiyFhov7Xnuc6bHFW6ZxwsgIbiQ99Hz7oNG7219oj9AsCnznCEvOKPDzdHRY73vYJjv7uQfFyffV8eUvvH2_uLi_u6Sgkz1TxWjnXtF45peWirETVlAulSq2VbEvhGucbJ0HYpuLaWdEyL1vd1tqWwrJGHhQnm90xhvcJUjZLTA763g4QpmR4yThrtK6rOSo20TRGHF4hmrcwxWH-znBm1mjMBo2Z0Zg1GiPkD2IMhmE</recordid><startdate>20130701</startdate><enddate>20130701</enddate><creator>Suzuki, Takeshi</creator><creator>Horikoshi, Masanobu</creator><creator>Sugihara, Makoto</creator><creator>Hirota, Tomoya</creator><creator>Ogishima, Hiroshi</creator><creator>Umeda, Naoto</creator><creator>Kondo, Yuya</creator><creator>Tsuboi, Hiroto</creator><creator>Hayashi, Taichi</creator><creator>Chino, Yusuke</creator><creator>Matsumoto, Isao</creator><creator>Sumida, Takayuki</creator><general>Springer Japan</general><scope>7X8</scope></search><sort><creationdate>20130701</creationdate><title>Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI</title><author>Suzuki, Takeshi ; Horikoshi, Masanobu ; Sugihara, Makoto ; Hirota, Tomoya ; Ogishima, Hiroshi ; Umeda, Naoto ; Kondo, Yuya ; Tsuboi, Hiroto ; Hayashi, Taichi ; Chino, Yusuke ; Matsumoto, Isao ; Sumida, Takayuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p231t-5175cc8bf5c593d462684d5549953b42c8cf8c3e2a8619ca2b0f3b9b79a42a083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Rheumatology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suzuki, Takeshi</creatorcontrib><creatorcontrib>Horikoshi, Masanobu</creatorcontrib><creatorcontrib>Sugihara, Makoto</creatorcontrib><creatorcontrib>Hirota, Tomoya</creatorcontrib><creatorcontrib>Ogishima, Hiroshi</creatorcontrib><creatorcontrib>Umeda, Naoto</creatorcontrib><creatorcontrib>Kondo, Yuya</creatorcontrib><creatorcontrib>Tsuboi, Hiroto</creatorcontrib><creatorcontrib>Hayashi, Taichi</creatorcontrib><creatorcontrib>Chino, Yusuke</creatorcontrib><creatorcontrib>Matsumoto, Isao</creatorcontrib><creatorcontrib>Sumida, Takayuki</creatorcontrib><collection>MEDLINE - Academic</collection><jtitle>Modern rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suzuki, Takeshi</au><au>Horikoshi, Masanobu</au><au>Sugihara, Makoto</au><au>Hirota, Tomoya</au><au>Ogishima, Hiroshi</au><au>Umeda, Naoto</au><au>Kondo, Yuya</au><au>Tsuboi, Hiroto</au><au>Hayashi, Taichi</au><au>Chino, Yusuke</au><au>Matsumoto, Isao</au><au>Sumida, Takayuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI</atitle><jtitle>Modern rheumatology</jtitle><stitle>Mod Rheumatol</stitle><date>2013-07-01</date><risdate>2013</risdate><volume>23</volume><issue>4</issue><spage>782</spage><epage>787</epage><pages>782-787</pages><issn>1439-7595</issn><eissn>1439-7609</eissn><abstract>Objective Tocilizumab (TCZ) is effective in patients with rheumatoid arthritis (RA) who are refractory to anti-tumor-necrosis-factor (anti-TNF) biologics. The Rheumatoid Arthritis Society Disease Activity Score in 28 Joints (DAS28) is used to evaluate the response to TCZ. However, DAS28 is inappropriate marker because TCZ normalizes C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in the early stage of treatment. The aim of our study was to test the usefulness of magnetic resonance imaging (MRI)-based markers of response to TCZ treatment. Methods Nine patients with RA who were refractory to anti-TNF inhibitors (six to infliximab, one to etanercept, one to adalimumab, and one to both) were assessed. MRI images of both hands were obtained by low-field extremity MRI at baseline, 20, and 44 weeks of treatment, in addition to assessment with DAS28–ESR. The effect of TCZ on RA was examined by compact MRI score (cMRIS). Results All patients showed good or moderate response to TCZ treatment, as evaluated by significant reduction in DAS28–ESR at both 20 and 44 weeks ( p  &lt; 0.001, each, relative to baseline). In contrast, MRI-based indexes (e.g., cMRIS, synovitis, edema, erosion scores) improved significantly at 44 weeks but not at 20 weeks. Conclusion Differences in response to TCZ therapy were determined based on the method of evaluation, suggesting that MRI-based markers are potentially useful for evaluating RA response to TCZ therapy.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><doi>10.1007/s10165-012-0746-2</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1439-7595
ispartof Modern rheumatology, 2013-07, Vol.23 (4), p.782-787
issn 1439-7595
1439-7609
language eng
recordid cdi_proquest_miscellaneous_1401089976
source Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)
subjects Medicine
Medicine & Public Health
Original Article
Orthopedics
Rheumatology
title Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T20%3A40%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_sprin&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20efficacy%20of%20tocilizumab%20in%20patients%20with%20rheumatoid%20arthritis%20refractory%20to%20anti-tumor-necrosis-factor%20inhibitors:%201%20year%20follow-up%20with%20low-field%20extremity%20MRI&rft.jtitle=Modern%20rheumatology&rft.au=Suzuki,%20Takeshi&rft.date=2013-07-01&rft.volume=23&rft.issue=4&rft.spage=782&rft.epage=787&rft.pages=782-787&rft.issn=1439-7595&rft.eissn=1439-7609&rft_id=info:doi/10.1007/s10165-012-0746-2&rft_dat=%3Cproquest_sprin%3E1401089976%3C/proquest_sprin%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p231t-5175cc8bf5c593d462684d5549953b42c8cf8c3e2a8619ca2b0f3b9b79a42a083%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1401089976&rft_id=info:pmid/&rfr_iscdi=true